Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer.
[BACKGROUND/OBJECTIVES] Positive peritoneal cytology (Cy+) is considered a form of microscopic dissemination and a poor prognostic factor in resected pancreatic cancer (PC).
- p-value P < 0.01
- p-value P = 0.01
APA
Tanaka H, Hirabayashi K, et al. (2025). Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 25(4), 544-551. https://doi.org/10.1016/j.pan.2025.05.006
MLA
Tanaka H, et al.. "Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer.." Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], vol. 25, no. 4, 2025, pp. 544-551.
PMID
40442012
Abstract
[BACKGROUND/OBJECTIVES] Positive peritoneal cytology (Cy+) is considered a form of microscopic dissemination and a poor prognostic factor in resected pancreatic cancer (PC). However, the clinical implications of equivocal categories such as atypia of undetermined significance (AUS) and suspicious for malignancy (SFM) remain unclear.
[METHODS] We retrospectively analyzed patients with PC who underwent surgery at 13 high-volume centers between January 2009 and December 2018. Inclusion criteria were: 1) cytology results of AUS, SFM, or malignant (MAL); 2) resectable (R) or borderline resectable (BR); 3) no other macroscopic metastases; and 4) no preoperative therapy.
[RESULTS] A total of 239 cases were included (AUS: 58, SFM: 31, MAL: 150), with R/BR = 196/43. Survival curves for SFM closely resembled those for MAL but differed from AUS. Grouped analysis showed that SFM + MAL patients had significantly shorter median overall survival (OS) than AUS patients (19.6 vs. 28.0 months, HR 1.61, P < 0.01) and shorter recurrence-free survival (RFS: 8.0 vs. 12.7 months, HR 1.53, P = 0.01). This trend persisted in resectable cases (OS: 21.1 vs. 30.5 months, HR 1.74; RFS: 9.1 vs. 14.2 months, HR 1.57; all P < 0.01).
[CONCLUSIONS] The cytology of SFM in PC is associated with a prognosis comparable to that of MAL, suggesting the need for cautious clinical interpretation and potential reclassification.
[METHODS] We retrospectively analyzed patients with PC who underwent surgery at 13 high-volume centers between January 2009 and December 2018. Inclusion criteria were: 1) cytology results of AUS, SFM, or malignant (MAL); 2) resectable (R) or borderline resectable (BR); 3) no other macroscopic metastases; and 4) no preoperative therapy.
[RESULTS] A total of 239 cases were included (AUS: 58, SFM: 31, MAL: 150), with R/BR = 196/43. Survival curves for SFM closely resembled those for MAL but differed from AUS. Grouped analysis showed that SFM + MAL patients had significantly shorter median overall survival (OS) than AUS patients (19.6 vs. 28.0 months, HR 1.61, P < 0.01) and shorter recurrence-free survival (RFS: 8.0 vs. 12.7 months, HR 1.53, P = 0.01). This trend persisted in resectable cases (OS: 21.1 vs. 30.5 months, HR 1.74; RFS: 9.1 vs. 14.2 months, HR 1.57; all P < 0.01).
[CONCLUSIONS] The cytology of SFM in PC is associated with a prognosis comparable to that of MAL, suggesting the need for cautious clinical interpretation and potential reclassification.
MeSH Terms
Humans; Pancreatic Neoplasms; Female; Male; Middle Aged; Aged; Retrospective Studies; Peritoneum; Aged, 80 and over; Prognosis; Peritoneal Neoplasms; Adult; Cytodiagnosis; Clinical Relevance
같은 제1저자의 인용 많은 논문 (4)
- Fatty acid-induced lipid accumulation promotes radiosensitization in Huh7 hepatocellular carcinoma cells.
- Educational inequalities in site-specific cancer mortality: a Japanese census-linked study.
- Impact of Approach Routes in MRI-Ultrasound Fusion Prostate Biopsy on Post-Biopsy Complications: A Propensity Score-Matched Analysis.
- FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (GEMINI-PC-01).